➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Dow
Harvard Business School
McKesson
Mallinckrodt

Last Updated: August 15, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR COMETRIQ

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for COMETRIQ

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01703065 Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer Recruiting National Cancer Institute (NCI) N/A 2013-09-01 This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01703065 Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer Recruiting Prostate Cancer Foundation N/A 2013-09-01 This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01703065 Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer Recruiting University of Washington N/A 2013-09-01 This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for COMETRIQ

Condition Name

Condition Name for COMETRIQ
Intervention Trials
Clear Cell Renal Cell Carcinoma 3
Recurrent Renal Cell Carcinoma 2
Kidney Medullary Carcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for COMETRIQ
Intervention Trials
Carcinoma 20
Adenocarcinoma 6
Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for COMETRIQ

Trials by Country

Trials by Country for COMETRIQ
Location Trials
United States 290
Canada 9
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for COMETRIQ
Location Trials
California 13
Pennsylvania 12
Massachusetts 11
Ohio 11
Illinois 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for COMETRIQ

Clinical Trial Phase

Clinical Trial Phase for COMETRIQ
Clinical Trial Phase Trials
Phase 2 26
Phase 1/Phase 2 1
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for COMETRIQ
Clinical Trial Phase Trials
Not yet recruiting 13
Active, not recruiting 9
Recruiting 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for COMETRIQ

Sponsor Name

Sponsor Name for COMETRIQ
Sponsor Trials
National Cancer Institute (NCI) 24
Exelixis 10
University of Washington 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for COMETRIQ
Sponsor Trials
NIH 24
Other 15
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Mallinckrodt
Baxter
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.